NCT05232175View on ClinicalTrials.gov

Clinical Study of ALT-BB4 to Determine Tolerance, Safety and Pharmacokinetics in Healthy Volunteer

PHASE1CompletedINTERVENTIONAL
Enrollment

290

Participants

Timeline

Start Date

January 18, 2022

Primary Completion Date

August 24, 2022

Study Completion Date

August 24, 2022

Conditions
Health, Subjective
Interventions
DRUG

ALT-BB4

Recombinant Hyaluronidase

DRUG

0.9%NaCl

Normal Saline

Trial Locations (1)

Unknown

Research Site, Seoul

Sponsors

Lead Sponsor

Alteogen, Inc.
All Listed Sponsors
lead

Alteogen, Inc.

INDUSTRY

NCT05232175 - Clinical Study of ALT-BB4 to Determine Tolerance, Safety and Pharmacokinetics in Healthy Volunteer | Biotech Hunter | Biotech Hunter